Disease Info Card

Von Hippel-lindau Syndrome

Information about Von Hippel-lindau Syndrome: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Von Hippel-lindau Syndrome

Most recent studies have shown that Von Hippel-lindau Syndrome shares some biological mechanisms with adrenal-gland-neoplasms, angiomatosis, carcinoma, cell-transformation-neoplastic, cerebellar-neoplasms, conventional-(clear-cell)-renal-cell-carcinoma, endocrine-gland-neoplasms, hemangioblastoma, hypoxia, kidney-neoplasm, malignant-neoplasm-of-kidney, malignant-neoplasms, malignant-paraganglionic-neoplasm, multiple-endocrine-neoplasia, neoplasm-metastasis, neoplasms, nervousness, neurofibromatosis-1, pheochromocytoma, renal-cell-carcinoma.

Among the many pathways, these few ones have gauged particular interests from scientists studying Von Hippel-lindau Syndrome, and have been seen in publications frequently: Angiogenesis, Cell Adhesion, Cell Cycle, Cell Death, Cell Growth, Cell Proliferation, Dna Methylation, Enucleation, Gene Silencing, Glycolysis, Localization, Methylation, Oncogenesis, Oxygen Homeostasis, Pathogenesis, Proteolysis, Response To Hypoxia, Rna Interference, Secretion, Translation

Quite a number of genes have been found to play important roles in Von Hippel-lindau Syndrome, such as CA9, CDKN2A, EPAS1, EPO, HIF1A, MTOR, MUL1, RET, SDHB, SDHC, SDHD, SETD2, TP53, TRIM50, VEGFA, VHL, XRCC1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.